Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical research study is to establish the maximum tolerated dose and recommended Phase II dose of Erbitux™ in combination with Irinotecan in pediatric and adolescent patients with refractory solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: ImClone LLC
• Treatments: Camptothecin; Cetuximab; Irinotecan

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of a solid tumor which has progressed on, or following standard therapy, or for which no standard effective therapy is known.

• Children age 1-18 years.

Exclusion Criteria:

• Presence of active infection.

• Requirement to receive concurrent chemotherapy immunotherapy, radiotherapy, or any other investigational drug while on study.

• Inadequate bone marrow, hepatic, or renal function.